First-of-its-kind data center ABS program created for Cloud Capital’s Core Strategy with the first-ever data center ABS issuance with a Triple-A rating from three independent agencies.

WASHINGTON, July 29, 2026 /PRNewswire/ — Cloud Capital, a leading global data center investment management firm, today announced the successful closing of a $520 million asset-backed securities (ABS) issuance through its newly established Cloud Capital ABS Master Trust, the second ABS Master Trust managed by Cloud Capital.

This structure is designed to provide a scalable and repeatable financing platform for Cloud Capital’s stabilized Core Joint Venture Strategy, which is backed by Realty Income and a leading global institutional investor, and marks the launch of the industry’s first programmatic data center ABS Master Trust set-up for a core joint venture. The transaction is the first data center ABS issuance to achieve triple-A ratings from three independent rating agencies.  Structured as a single A-2-I tranche and rated AAA by Fitch Ratings, Morningstar DBRS and Kroll Bond Rating Agency reflects the quality of the underlying assets, conservative capital stack and long-term contracted cash flows.

The issuance is secured by an 80 MW stabilized hyperscale data center in Northern Virginia, leased to an investment-grade hyperscale customer under a long-term lease supported by durable, and mission-critical workloads. 

“The launch of our ABS Master Trust represents another defining milestone in Cloud Capital’s evolution as a leading institutional investment platform for digital infrastructure,” said Hossein Fateh, Founder and Chief Executive Officer of Cloud Capital. “We have established a scalable source of long-term capital that will support the continued growth of our Core Strategy while enhancing value for our institutional investors. Achieving Triple-A ratings from three independent agencies reflects the exceptional quality of our assets, disciplined underwriting, and long-standing relationships with investment-grade hyperscale customers.”

“Despite challenging market conditions, this transaction received significant demand from a broad and diversified institutional investor group and matched the tightest spread for a data center ABS transaction since the onset of the conflict in the Middle East in 2026,” said Jason Weaver, Executive Vice President and Head of Capital Markets at Cloud Capital. “Beyond the successful execution of this issuance, these facilities establish a repeatable financing platform that expands our access to institutional capital, diversifies our funding sources, enhances capital efficiency and positions Cloud Capital to finance future growth at an increasingly competitive cost of capital. We are grateful to our financial advisors and investors for their continued support as we grow our platform.”

Matt Bissonette, Senior Managing Director of Guggenheim Securities, LLC, added, “Cloud Capital has established a new benchmark for institutional financing in the digital infrastructure sector. The combination of premier stabilized assets, long-duration investment-grade tenancy, conservative down-the-fairway structuring and an innovative Master Trust framework generated exceptional demand across a broad spectrum of institutional investors. This transaction demonstrates both the continued maturation of the data center ABS market and the growing demand for high-quality digital infrastructure credit.”

The net proceeds from the transaction will support the continued growth of Cloud Capital’s Core Strategy and provide additional flexibility to capitalize on the increasing global demand for hyperscale digital infrastructure.

The transaction was led by Guggenheim Securities, LLC as the Sole Structuring Advisor and Sole Active Bookrunning Manager. In addition, Deutsche Bank Securities Inc. and Morgan Stanley & Co. LLC acted as Passive Bookrunners.

About Cloud Capital

Cloud Capital is a leading global specialized investment management firm focused on acquiring, managing and operating high-quality data centers. Since 2020, Cloud Capital has acquired a portfolio of 30 data center assets worldwide valued at over $12 billion, employing a rigorous and disciplined underwriting process for both proprietary and off-market data center transactions and active hands-on asset management. Cloud Capital has offices in Washington, D.C., San Francisco, CA, and London.

For more information, please visit: www.cloudcapital.com

Contact: info@cloudcapital.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cloud-capital-launches-new-data-center-abs-master-trust-completes-520-million-triple-a-rated-issuance-302838401.html

SOURCE Cloud Capital

SAN DIEGO, July 29, 2026 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Photronics, Inc. (NASDAQ: PLAB) securities between December 10, 2025 and May 27, 2026, inclusive (the “Class Period”), have until Friday, September 4, 2026 to seek appointment as lead plaintiff of the Photronics class action lawsuit.  Captioned Cooper v. Photronics, Inc., No. 26-cv-01069 (D. Conn.), the Photronics class action lawsuit charges Photronics and certain of Photronics’ top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Photronics class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-photronics-inc-class-action-lawsuit-plab.html 

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com.

CASE ALLEGATIONS: Photronics, together with its subsidiaries, engages in the manufacture and sale of photomask products and services.

The Photronics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Photronics’ projected revenue outlook and anticipated growth, while also minimizing risks from post-holiday seasonality and macroeconomic fluctuations; and (ii) Photronics’ high-end chip design release pipeline was experiencing severe, ongoing bottlenecks due to elevated foundry utilization rates and equipment cost pressures that rendered its forward growth expectations unachievable.

On May 28, 2026, Photronics announced its financial results for the second quarter of fiscal 2026, allegedly revealing revenue and earnings well below internal projections and highlighting a critical collapse of integrated circuit revenue by 11% sequentially.  On this news, the price of Photronics stock dropped more than 36%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Photronics securities during the Class Period to seek appointment as lead plaintiff in the Photronics class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Photronics class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Photronics class action lawsuit.  An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Photronics class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation.  Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025.  This marks our fourth #1 ranking in the past five years.  And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm.  With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 

Services may be performed by attorneys in any of our offices. 

Contact:

          Robbins Geller Rudman & Dowd LLP
          Ken Dolitsky
          Michael Albert
          655 W. Broadway, Suite 1900, San Diego, CA 92101
          800/851-7783
          info@rgrdlaw.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-notice-robbins-geller-rudman–dowd-llp-announces-that-photronics-inc-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit—plab-302834744.html

SOURCE Robbins Geller Rudman & Dowd LLP

Ember offers Japanese market pharmaceutical transportation solution integrating temperature control, visualization of transportation status and traceability

LOS ANGELES, July 29, 2026 /PRNewswire/ — Ember LifeSciences, Inc. (“Ember”), an award-winning provider of advanced pharmaceutical cold chain solutions, has entered into a capital and business alliance with Alfresa Corporation (“Alfresa”), a subsidiary of Alfresa Holdings Corporation.

The Alfresa Group has the No. 1 domestic net sales in the pharmaceutical wholesale business in Japan. Alfresa will partner with Ember to improve the quality of pharmaceutical cold chain logistics across Japan, including evaluating the Ember Cube and related technologies for Alfresa’s Home Care Delivery service, which delivers specialty pharmaceuticals directly from medical institutions to patients’ homes.

As part of the new alliance, Alfresa will provide financial support for Ember’s business expansion through an investment in Series A preferred stock issued by Ember, strengthening collaboration between the two companies. Other investors in the Ember Series A include Amgen, Cardinal Health, Carrier and Sea Court Capital. Through the agreement, Alfresa obtains the exclusive sales rights in Japan’s healthcare sector for solutions provided by Ember.

“We are deeply honored to partner with Alfresa, a company whose legacy of excellence and market leadership we hold in the highest regard,” said Clay Alexander, Ember founder and CEO. “As our Ember Cube 2 continues to gain international acclaim for its revolutionary design, this strategic investment and distribution alliance marks a pivotal milestone. Together, Alfresa and Ember share a profound commitment to bringing unprecedented precision, confidence and reliability to pharmaceutical cold chain logistics for patients throughout Japan.”

“The rapid growth of biopharmaceuticals and vaccines — with the number of temperature‑sensitive products increasing each year — demands absolute precision in cold chain logistics,” said Yusuke Fukujin, representative director and president, Alfresa. “Alfresa has been strengthening its capabilities in this space through continuous investment in next generation technologies. I am very excited about this partnership with Ember, which reinforces our commitment to advance cold chain pharmaceutical logistics in the Japanese market.”

Ember provides pharmaceutical manufacturers, distributors and healthcare providers with cold chain solutions that combine temperature control with real-time shipment visibility. The Ember Cube 2, which recently earned the Best of the Best Red Dot Design Award, maintains a temperature range of 2°C to 8°C for more than 72 hours while continuously monitoring shipment conditions and location. Its reusable design also helps reduce packaging waste compared with traditional single-use shipping materials.

About Ember LifeSciences
Ember LifeSciences initially launched as an offshoot of Ember Technologies’ “Ember,” the design-led temperature control brand and maker of the award-winning temperature control mug, which has surpassed half a billion dollars in total sales to date. Ember seeks to redefine global medicine distribution through leveraging Ember’s proprietary temperature control technology to improve the way we transport life-saving medicines and vaccines around the world. To learn more about Ember LifeSciences, visit emberlifesciences.com.

Media Contact
Meghan Bianco
embermedia@rfbinder.com

About the Alfresa Group
The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: https://www.alfresa.com/eng/ 

Media Contact
ir@alfresa.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ember-lifesciences-and-alfresa-corporation-enter-into-capital-and-business-alliance-to-improve-the-quality-of-the-pharmaceutical-cold-chain-in-japan-302838262.html

SOURCE Ember LifeSciences, Inc.